Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0113-5840 in Overweight or Obesity
NCT07566390Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- May 2026
- Primary completion
- Jan 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC0113-5840 in obesity (7 arms), sponsored by Novo Nordisk. Primary endpoint: Number of treatment emergent adverse events at Day 43. Started May 2026; status: recruiting.
02
Drugs
NNC0113-5840
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07566390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07566390.